FGAM
BCRX icon

Financial Gravity Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Financial Gravity Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25
Closed -$121 – 1540
2024
Q1 		$121 Buy
25
+21
+525% +$118 ﹤0.01% 1702
2023
Q4 		$20 Buy
4
+2
+100% +$12 ﹤0.01% 1431
2023
Q3 		$10 Sell
2
-5
-71% -$36 ﹤0.01% 1161
2023
Q2 		$37 Sell
7
-1
-13% -$8 ﹤0.01% 1434
2023
Q1 		$14 Sell
8
-3
-27% -$29 ﹤0.01% 824
2022
Q4 		$62 Sell
11
-15
-58% -$187 ﹤0.01% 1194
2022
Q3 		$21 Buy
26
+4
+18% +$51 ﹤0.01% 716
2022
Q2 		$18 Sell
22
-10
-31% -$103 ﹤0.01% 647
2022
Q1 		$28 Buy
32
+4
+14% +$64 ﹤0.01% 686
2021
Q4 		$24 Buy
28
+26
+1,300% +$344 ﹤0.01% 811
2021
Q3 		$14K Hold
2
– – 0.01% 844
2021
Q2 		$16K Sell
2
-3
-60% -$41 0.01% 846
2021
Q1 		$55 Buy
+5
New +$52 ﹤0.01% 546

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Financial Gravity Asset Management's BCRX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 25 shares — an estimated $121 sold.

Financial Gravity Asset Management first reported a position in BCRX in Q1 2021 and held it in 13 quarters. The position peaked at $16K in Q2 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 25 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $121.
  • Financial Gravity Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Financial Gravity Asset Management's BioCryst Pharmaceuticals position peaked at $16K in Q2 2021.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.